A phase Ib open-label, dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with abiraterone or enzalutamide in metastatic castrate-resistant prostate cancer.

被引：5

作者：

Vaishampayan, Ulka N.

Narayan, Vivek

Wise, David

Lang, Joshua Michael

Lowentritt, Benjamin H.

Mellado, Begona

Carles, Joan

Saez, M. Isabel

Abida, Wassim

Taplin, Mary-Ellen

Azad, Arun

Wang, Karrie

Barbash, Olena

Ferron-Brady, Geraldine

Fecteau, Doug

Khaled, Ahmed Hussein

Dhar, Arindam

De Bono, Johann S.

机构：

[1] Karmanos Canc Ctr, Detroit, MI USA

[2] Penn Med Abramson Canc Ctr, Philadelphia, PA USA

[3] New York Univ Med Ctr, New York, NY USA

[4] Univ Wisconsin Carbone Canc Ctr, Madison, WI USA

[5] Chesapeake Urol Associates, Towson, MD USA

[6] Hosp Clin Barcelona, Barcelona, Spain

[7] Vall Hebron Univ Hosp Inst Oncol, Barcelona, Spain

[8] H Univ Virgen Victoria Reg Malaga, Inst Biomed Res Malaga CNIO IBIMA Genitourinary C, CRIS Canc Fdn Prostate Canc Res Grp, Malaga, Spain

[9] Mem Sloan Kettering Canc Ctr, New York, NY USA

[10] Dana Farber Canc Inst, Boston, MA USA

[11] Monash Univ, Clayton, Vic, Australia

[12] GlaxoSmithKline, Collegeville, PA USA

[13] Inst Canc Res & Royal Marsden Hosp, London, England

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.TPS391

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS391

引用

页数：1

共 50 条

[41] ODENZA, a Prospective, Randomized, Open-Label, Multicenter, Cross-Over Phase 2 Trial of Preference Between Darolutamide and Enzalutamide in Men With Asymptomatic or Mildly Symptomatic Metastatic Castrate-Resistant Prostate Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (08) : 16 - 17
[42] An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer
Liu, Joyce
Burris, Howard
Wang, Judy S.
Barroilhet, Lisa
Gutierrez, Martin
Wang, Yulei
Vaze, Anjali
Commerford, Renee
Royer-Joo, Stephanie
Choeurng, Voleak
Humke, Eric
Moore, Kathleen
GYNECOLOGIC ONCOLOGY, 2021, 163 (03) : 473 - 480
[43] Results of preclinical and clinical phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in castrate-resistant prostate cancer
Montgomery, Bruce
Morris, Michael
Ryan, Charles
Corey, Eva
Stickney, Dwight
Frincke, James
Reading, Chris
Scher, Howard
MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
[44] A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib plus rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC).
Pook, David William
Geynisman, Daniel M.
Carles, Joan
De Braud, Filippo G.
Joshua, Anthony M.
Perez-Gracia, Jose Luis
Perez, Casilda Llacer
Shin, Sang Joon
Fang, Bruno
Barve, Minal A.
Maruzzo, Marco
Bracarda, Sergio
Kim, Miso
Kerloeguen, Yannick
Gallo, Jorge Daniel
Maund, Sophia
Harris, Adam
Huang, Kuan-Chieh
Sutaria, Dhruvitkumar S.
Gurney, Howard
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[45] A phase 1 open-label, dose-escalation study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide (previously MDV3100) alone or in combination with an aromatase inhibitor in women with advanced breast cancer
Traina, T. A.
Yardley, D. A.
Patel, M.
Schwartzberg, L.
Elias, A.
Gucalp, A.
Peterson, A. C.
Hannah, A.
Gibbons, J.
Khondker, Z.
Hudis, C. A.
LoRusso, P.
CANCER RESEARCH, 2013, 73
[46] A Phase I, Open-Label, Dose-Finding Study of GSK2636771, a PI3Kβ Inhibitor, Administered with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer
Sarker, Debashis
Dawson, Nancy A.
Aparicio, Ana M.
Dorff, Tanya B.
Pantuck, Allan J.
Vaishampayan, Ulka N.
Henson, Lynn
Vasist, Lakshmi
Roy-Ghanta, Sumita
Gorczyca, Michele
York, Whitney
Ganji, Gopinath
Tolson, Jerry
de Bono, Johann S.
CLINICAL CANCER RESEARCH, 2021, 27 (19) : 5248 - 5257
[47] A phase I open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a trispecific Humabody T-cell enhancer, in patients with PSMA plus advanced and/or metastatic solid tumors (POTENTIA).
Hashimoto, Kenji
Pierce, Andrew J.
Chau, Albert
Bartlett, Phillip
Lloyd, Peter
Maginn, Mark
Machacek, Matthias
Vollmer, Jannik
Rajbally, Sultanah
Tilson, Julia
Bland-Ward, Phil
CANCER RESEARCH, 2021, 81 (13)
[48] A phase 1 open-label, dose escalation and expansion trial to investigate the safety, pharmacokinetics and pharmacodynamics of CB307, a Trispecific Humabody® T-cell enhancer, in patients with PSMA plus advanced and/or metastatic solid tumors (POTENTIA).
de Bono, Johann S.
Arkenau, Hendrik-Tobias
Gort, Eelke H.
Devriese, Lot L.
Fontana, Elisa
Knapen, Daan G.
Tiu, Crescens
Williams, Anja
de Groot, Derk Jan A.
Gunaydin, Ulug M.
Bartlett, Phillip
Pierce, Andrew J.
Bland-Ward, Philip
Hashimoto, Kenji
de Vries, E. G. Elisabeth
CANCER RESEARCH, 2022, 82 (12)
[49] ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with metastatic castrate resistant prostate cancer
Subudhi, S. K.
Wise, D.
Liu, S. T.
Chaudhry, A.
Kim, J.
Gardner, O.
Gilbert, H.
Grady, M.
Paoloni, M.
Krishnan, K.
Carducci, M.
ANNALS OF ONCOLOGY, 2020, 31 : S545 - S545
[50] ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).
Colomba, Emeline
Jonas, Sarah Flora
Eymard, Jean-Christophe
Delva, Remy
Brachet, Pierre-Emmanuel
Neuzillet, Yann
Penel, Nicolas
Roubaud, Guilhem
Bompas, Emmanuelle
Mahammedi, Hakim
Longo, Raffaele
Helissey, Carole
Barthelemy, Philippe
Borchiellini, Delphine
Hasbini, Ali
Priou, Franck
Saldana, Carolina
Voog, Eric
Foulon, Stephanie
Fizazi, Karim
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →